September 13, 2010
Mount Sinai Performs First Tricuspid Ring Implantation
David H. Adams, MD, Marie-Jos©e and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center, has performed the first implantation of the Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring in the United States. Dr. Adams invented the ring, which was recently approved by the Food and Drug Administration.
The tricuspid valve lies between the right atrium and right ventricle of the heart. Tricuspid valve regurgitation occurs when the valve does not close completely and blood leaks back into the right atrium of the heart. If left untreated, tricuspid valve regurgitation can lead to debilitating symptoms including congestive heart failure and irreversible heart damage. Both American and European guidelines for heart valve disease management now emphasize the importance of treating the diseased tricuspid valve at the time of mitral valve surgery.
Until recently, "surgical abstention" has been the norm in dealing with functional tricuspid regurgitation, with the assumption that tricuspid regurgitation should resolve once the primary cause"”typically mitral stenosis or regurgitation"”is eliminated. Annuloplasty rings are specially designed to help restore the tricuspid valve to its normal size and shape"”the valve is often enlarged or distorted in a diseased state.
"We also increased the open side of the new ring to better accommodate the heart's conduction system, which is intimately associated with the tricuspid valve. So in addition to a more advanced physiologic repair concept, the Tri-Ad ring design will also protect against damage to the electrical system of the heart," said Dr. Adams.
On the Net: